1.Design and development of Remote ECG Monitoring System
Xing LIU ; Xichao CHEN ; Juemin WANG ; Wei XIE
Chinese Medical Equipment Journal 2003;0(11):-
Along with the development of modern communication technology,remote patient monitoring,especially remote ECG monitoring is widely applied in medical field.The history of remote ECG monitoring is introduced,and then a Remote ECG Monitoring System which has been applied in our hospital is mainly present,including the system structure,the design of ECG acquisition and the design of acquisition station.
2.Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer
Zhe CHEN ; Xiaofeng ZHAI ; Yonghua SU ; Xuying WAN ; Jin LI ; Juemin XIE ; Bo GAO
Journal of Integrative Medicine 2003;1(3):184-6
OBJECTIVE: To observe the clinical effect of cinobufacini injection in treating moderate and advanced primary liver cancer (PLC). METHODS: One hundred patients with moderate and advanced PLC were randomly divided into cino-treated group (50 patients) and control group (50 patients). The quality of life, tumor size, some changes of laboratory tests, and survival time were observed. RESULTS: The progressive rate of cino-treated group (18%) was lower than that of the control group (32%). The quality of life of the cino-treated group (80%) was better than that of the control group (72%), but without statistical significance. The survival rate of >12 months of the cino-treated group (30%) was higher than that of the control group (18%). The patients' liver function such as serum total bilirubin and ALT decreased obviously in the cino-treated group while increased a lot in the control group. The level of AFP increased after treatment with statistical significance in the control group while there was no statistical significance in the cino-treated group. CONCLUSION: Cinobufacini injection can not only inhibit the proliferation of cancer, but also protect liver function, improve quality of life and prolong survival time.
3.HPLC separation and determination of bufadienolide in Cinobufacini Injection
Yonghua SU ; Xueqiang HUANG ; Dazhi ZHANG ; Yani ZHANG ; Juemin XIE ; Changquan LING ;
Chinese Traditional Patent Medicine 1992;0(01):-
Objective: To determinate the content of bufalin,resibufogenin and cinobufagin in Cinobufacini Injection. Methods: Liposoluble components in cinobufacini were extracted with ethyl acetate and determined by HPLC using a C 18 column, acetonitrile water(50∶50) as a mobile phase and UV detection wavelength at 299nm. Results: The method showed the good resolution, high sensitivity, satisfactory accuracy and specificity. Quantitatively analyze results showed that the concentration of bufalin, cinobufagin and resibufogenin in Cinobufacini Injection were 0.333 ?g?mL -1 , 0.159?g?mL -1 and 0.110?g?mL -1 , respectively. Conclusion: Bufalin in Cinobufacini Injection reached effective concentration, which was regarded as one of anti cancer components.
4.Right ventricular-pulmonary artery connection for palliative treatment of pulmonary atresia with ventricular septal defect in children: A single-center retrospective study
Shuai ZHANG ; Jianrui MA ; Hailong QIU ; Xinjian YAN ; Wen XIE ; Qiushi REN ; Juemin YU ; Tianyu CHEN ; Yong ZHANG ; Xiaohua LI ; Furong LIU ; Shusheng WEN ; Jian ZHUANG ; Qiang GAO ; Jianzheng CEN
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2025;32(03):366-371
Objective To compare the benefits and drawbacks of primary patch expansion versus pericardial tube right ventricular-pulmonary artery connection in patients diagnosed with pulmonary atresia with ventricular septal defect (PA/VSD). Methods A retrospective study was conducted on patients diagnosed with PA/VSD who underwent primary right ventricular-pulmonary artery connection surgery at our center between 2010 and 2020. Patients were categorized into two groups based on the type of right ventricular-pulmonary artery connection: a pericardial tube group and a patch expansion group. Clinical data and imaging findings were compared between the two groups. Results A total of 51 patients were included in the study, comprising 31 males and 20 females, with a median age of 12.57 (4.57, 49.67) months. The pericardial tube group included 19 patients with a median age of 17.17 (7.33, 49.67) months, while the patch expansion group consisted of 32 patients with a median age of 8.58 (3.57, 52.72) months. In both groups, the diameter of pulmonary artery, McGoon index, and Nakata index significantly increased after treatment (P<0.001). However, the pericardial tube group exhibited a longer extracorporeal circulation time (P<0.001). The reoperation rate was notably high, with 74.51% of patients requiring further surgical intervention, including 26 (81.25%) patients in the patch expansion group and 12 (63.16%) patients in the pericardial tube group. No statistical differences were observed in long-term cure rates or mortality between the two groups (P>0.005). Conclusion In patients with PA/VSD, both patch expansion and pericardial tube right ventricular-pulmonary artery connection serve as effective initial palliative treatment strategies that promote pulmonary vessel development and provide a favorable foundation for subsequent radical operations. However, compared to the pericardial tube approach, the patch expansion technique is simpler to perform and preserves some intrinsic potential for pulmonary artery development, making it the preferred procedure.